Latest & greatest articles for Cardiogenic Shock

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Cardiogenic Shock or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Cardiogenic Shock and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Cardiogenic Shock

1. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. (Abstract)

Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. Acute myocardial infarction (AMI) complicated by cardiogenic shock is associated with substantial morbidity and mortality. Although intravascular microaxial left ventricular assist devices (LVADs) provide greater hemodynamic support as compared with intra (...) -aortic balloon pumps (IABPs), little is known about clinical outcomes associated with intravascular microaxial LVAD use in clinical practice.To examine outcomes among patients undergoing percutaneous coronary intervention (PCI) for AMI complicated by cardiogenic shock treated with mechanical circulatory support (MCS) devices.A propensity-matched registry-based retrospective cohort study of patients with AMI complicated by cardiogenic shock undergoing PCI between October 1, 2015, and December 31, 2017

2020 JAMA

2. SCAI clinical expert consensus statement on the classification of cardiogenic shock Full Text available with Trip Pro

SCAI clinical expert consensus statement on the classification of cardiogenic shock SCAI clinical expert consensus statement on the classification of cardiogenic shock - Baran - - Catheterization and Cardiovascular Interventions - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. VALVULAR AND STRUCTURAL (...) HEART DISEASES Free Access SCAI clinical expert consensus statement on the classification of cardiogenic shock This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019 Corresponding Author E-mail address: Sentara Heart Hospital, Division of Cardiology, Advanced Heart Failure Center and Eastern Virginia Medical School, Norfolk, Virginia

2019 Society for Cardiovascular Angiography and Interventions

3. Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction Full Text available with Trip Pro

Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction Experimental trials suggest improved outcome by mild therapeutic hypothermia for cardiogenic shock after acute myocardial infarction. The objective of this study was to investigate the hemodynamic effects of mild therapeutic hypothermia in patients with cardiogenic shock complicating acute myocardial infarction.Patients (n=40) with cardiogenic shock undergoing primary percutaneous coronary intervention without classic (...) hypothermia failed to show a substantial beneficial effect on cardiac power index at 24 hours in patients with cardiogenic shock after acute myocardial infarction.URL: https://www.clinicaltrials.gov . Unique identifier: NCT01890317.

2019 EvidenceUpdates

4. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial Full Text available with Trip Pro

Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial The role of intraaortic balloon counterpulsation (IABP) in cardiogenic shock is still a subject of intense debate despite the neutral results of the IABP-SHOCK II trial (Intraaortic Balloon Pump in Cardiogenic Shock II) with subsequent downgrading in international guidelines. So far, randomized data on the impact of IABP on long-term clinical (...) outcomes in patients with cardiogenic shock complicating acute myocardial infarction are lacking. Furthermore, only limited evidence is available on general long-term outcomes of patients with cardiogenic shock treated by contemporary practice.The IABP-SHOCK II trial is a multicenter, randomized, openlabel trial. Between 2009 and 2012, 600 patients with cardiogenic shock complicating acute myocardial infarction undergoing early revascularization were randomized to IABP versus control.Long-term follow

2019 EvidenceUpdates

5. Cardiogenic Shock after Nifedipine Administration in a Pregnant Patient: A Case Report and Review of the Literature Full Text available with Trip Pro

Cardiogenic Shock after Nifedipine Administration in a Pregnant Patient: A Case Report and Review of the Literature We present a case of a 21-year-old Caucasian woman at 27 weeks of pregnancy who was admitted to the obstetric department for pre-term labor. She received 10 mg of nifedipine 4 times in 1 h, according to the internal protocol. Shortly after, she brutally deteriorated with pulmonary edema and hypoxemia requiring transfer to the intensive care unit (ICU) for mechanical ventilation (...) . She finally improved and was successfully extubated after undergoing a percutaneous valvuloplasty of the mitral valve. This case illustrates a severe cardiogenic shock after administration of nifedipine for premature labor in a context of unknown rheumatic mitral stenosis. Nifedipine induces a reflex tachycardia that reduces the diastolic period and thereby precipitates pulmonary edema in case of mitral stenosis. This case emphasizes the fact that this drug may be severely harmful and should never

2018 Journal of translational internal medicine

6. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. Full Text available with Trip Pro

One-Year Outcomes after PCI Strategies in Cardiogenic Shock. Among patients with acute myocardial infarction, cardiogenic shock, and multivessel coronary artery disease, the risk of a composite of death from any cause or severe renal failure leading to renal-replacement therapy at 30 days was found to be lower with percutaneous coronary intervention (PCI) of the culprit lesion only than with immediate multivessel PCI. We evaluated clinical outcomes at 1 year.We randomly assigned 706 patients (...) myocardial infarction and cardiogenic shock, the risk of death or renal-replacement therapy at 30 days was lower with culprit-lesion-only PCI than with immediate multivessel PCI, and mortality did not differ significantly between the two groups at 1 year of follow-up. (Funded by the European Union Seventh Framework Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549 .).

2018 NEJM Controlled trial quality: predicted high

7. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction Full Text available with Trip Pro

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking.The goal of this paper was to compare in a prospective, double-blind, multicenter (...) compared with norepinephrine, including an increase in cardiac double product (p = 0.0002) and lactic acidosis from H2 to H24 (p < 0.0001).In patients with CS secondary to acute myocardial infarction, the use of epinephrine compared with norepinephrine was associated with similar effects on arterial pressure and cardiac index and a higher incidence of refractory shock. (Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock [OptimaCC]; NCT01367743

2018 EvidenceUpdates

8. Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Full Text available with Trip Pro

Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Heart failure (HF) is an impending complication to myocardial infarction. We hypothesized that the degree of complement activation reflects severity of HF following acute myocardial infarction.The LEAF trial (LEvosimendan in Acute heart Failure following myocardial infarction) evaluating 61 patients developing HF within 48 h after (...) percutaneous coronary intervention-treated ST-elevation myocardial infarction herein underwent a post hoc analysis. Blood samples were drawn from inclusion to Day 5 and at 42 day follow-up, and biomarkers were measured with enzyme immunoassays. Regional myocardial contractility was measured by echocardiography as wall motion score index (WMSI). The cardiogenic shock group (n = 9) was compared with the non-shock group (n = 52). Controls (n = 44) were age-matched and sex-matched healthy individuals. C4bc

2018 ESC heart failure Controlled trial quality: uncertain

9. Impella CP (Abiomed) for use in adult patients with cardiogenic shock

Impella CP (Abiomed) for use in adult patients with cardiogenic shock Impella CP (Abiomed) for use in adult patients with cardiogenic shock Impella CP (Abiomed) for use in adult patients with cardiogenic shock HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Impella CP (Abiomed) for use in adult patients (...) with cardiogenic shock. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Cardiogenic shock (CS) is an acute life-threatening condition resulting from inadequate blood circulation due to the inability of the heart (most often the left ventricle) to adequately meet systemic tissue demands for oxygen and nutrients. Technology Description: The Impella CP is an intravascular nonpulsatile axial blood pump designed to support the circulatory system during CS, low output

2018 Health Technology Assessment (HTA) Database.

10. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. Full Text available with Trip Pro

PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.In this multicenter trial, we randomly (...) assigned 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to one of two initial revascularization strategies: either PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, or immediate multivessel PCI. The primary end point was a composite of death or severe renal failure leading to renal-replacement therapy within 30 days after randomization. Safety end points included bleeding and stroke.At 30 days, the composite

2017 NEJM Controlled trial quality: predicted high

11. Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction Full Text available with Trip Pro

Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction Mortality in cardiogenic shock (CS) remains high. Early risk stratification is crucial to make adequate treatment decisions.This study sought to develop an easy-to-use, readily available risk prediction score for short-term mortality in patients with CS, derived from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial.The score was developed using a stepwise multivariable regression (...) increase in mortality between the different score categories (0 to 2 vs. 3 to 4: p = 0.04; 0 to 2 vs. 5 to 9: p = 0.008).The IABP-SHOCK II risk score can be easily calculated in daily clinical practice and strongly correlated with mortality in patients with infarct-related CS. It may help stratify patient risk for short-term mortality and might, thus, facilitate clinical decision making. (Intraaortic Balloon Pump in Cardiogenic Shock II [IABP-SHOCK II]; NCT00491036).Copyright © 2017 American College

2017 EvidenceUpdates

13. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses (...) cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association , MD, MSc, FAHA, Chair , MD, MHS, Vice Chair , RN, PhD, FAHA , MD, FAHA , MD, FAHA , MD , MD , MD, FAHA , MD , MD, PhD, FAHA , MD , and PharmD, FAHA MDOn behalf of the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular

2017 American Heart Association

14. Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction

Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction Article Text

2017 Evidence-Based Medicine

15. Clostridium perfringens sepsis complicated by right ventricular cardiogenic shock Full Text available with Trip Pro

Clostridium perfringens sepsis complicated by right ventricular cardiogenic shock Clostridium perfringens sepsis has been ascribed a dismal prognosis when associated with massive intravascular haemolysis. We present a 71-year-old woman's fatal case which was compounded by isolated right ventricular cardiogenic shock. In this context, combined use of transthoracic echocardiography and pulmonary artery catheter monitoring is able to yield an individualized hemodynamic resuscitation. We discuss

2016 Journal of the Intensive Care Society

16. Impella 2.5 system (Abiomed Inc.) for emergent hemodynamic cardiac support in patients with cardiogenic shock

Impella 2.5 system (Abiomed Inc.) for emergent hemodynamic cardiac support in patients with cardiogenic shock Impella 2.5 system (Abiomed Inc.) for emergent hemodynamic cardiac support in patients with cardiogenic shock Impella 2.5 system (Abiomed Inc.) for emergent hemodynamic cardiac support in patients with cardiogenic shock HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation HAYES, Inc.. Impella 2.5 system (Abiomed Inc.) for emergent hemodynamic cardiac support in patients with cardiogenic shock. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Heart; Hemodynamics; Humans; Shock, Cardiogenic Language Published English Country of organisation United States English summary An English language summary is available

2015 Health Technology Assessment (HTA) Database.

17. Impella 5.0 (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock

Impella 5.0 (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock Impella 5.0 (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock Impella 5.0 (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Impella 5.0 (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Hemodynamics; Humans; Shock, Cardiogenic Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite

2015 Health Technology Assessment (HTA) Database.

18. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score Full Text available with Trip Pro

Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score Extracorporeal membrane oxygenation (ECMO) may provide mechanical pulmonary and circulatory support for patients with cardiogenic shock refractory to conventional medical therapy. Prediction of survival in these patients may assist in management of these patients and comparison of results from different centers.To identify pre-ECMO factors which predict survival from refractory (...) cardiogenic shock requiring ECMO and create the survival after veno-arterial-ECMO (SAVE)-score.Patients with refractory cardiogenic shock treated with veno-arterial ECMO between January 2003 and December 2013 were extracted from the international Extracorporeal Life Support Organization registry. Multivariable logistic regression was performed using bootstrapping methodology with internal and external validation to identify factors independently associated with in-hospital survival. Of 3846 patients

2015 EvidenceUpdates

19. Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI)

Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI) BestBets: Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI) Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI) Report By: Jonathon Coates - Registrar Emergency Medicine & Intensive Care Medicine Search checked by Steve Mathieu - Consultant, Intensive Care Medicine & Anaesthetics Institution: Queen Alexandra Hospital, Portsmouth, UK Original institution (...) : Queen Alexandra Hospital, Portsmouth, UK Date Submitted: 15th September 2013 Date Completed: 26th February 2014 Last Modified: 26th February 2014 Status: Green (complete) Three Part Question In [adults suffering from a STEMI complicated by cardiogenic shock] does [treatment with levosimendan] [improve outcome]? Clinical Scenario A 56 year old is brought to the ED suffering from a STEMI. He is hypotensive and suffering from cardiogenic shock. He has been started on dobutamine but he has failed

2014 BestBETS

20. Evaluation of Intra-Aortic Balloon Support in cardiogenic shock.

Evaluation of Intra-Aortic Balloon Support in cardiogenic shock. BestBets: Evaluation of Intra-Aortic Balloon Support in cardiogenic shock. Evaluation of Intra-Aortic Balloon Support in cardiogenic shock. Report By: Dr. Joseph Humphrey and Dr Bryan Judge - Emergency Medicine Residents Search checked by Bernard A Foex - Consultant in Emergency Medicine and Critical Care Institution: Grand Rapids Medical Education Research Partners/Michigan State University, Michigan, USA Original institution (...) : Manchester Royal Infirmary, Oxford Road, Manchester, UK Date Submitted: 15th May 2013 Date Completed: 26th February 2014 Last Modified: 26th February 2014 Status: Green (complete) Three Part Question In [adult patients with cardiogenic shock following myocardial infarction ] [what is the usefulness] of [intra-aortic balloon support]? Clinical Scenario A 67-year-old man is brought to the emergency department. He is cold, clammy and confused. He is also hypotensive and an ECG shows that he has had an AMI

2014 BestBETS